A Phase 2 interventional study of vortioxetine 10 mg tablet and vortioxetine 20 mg tablet in Attention Deficit Hyperactivity Disorder, sponsored by H. Lundbeck A/S. Completed at 15 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-03-07.
Sponsored by H. Lundbeck A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 135th largest by enrollment of the 706 interventional ones that give a count, is one of 49 that started in 2014, is one of 80 in phase 2, and was the 413th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–17
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–13
National Institute of Mental Health (NIMH) · Sites in United States
Ages 10–17 · Healthy volunteers
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65
Alkermes, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
807 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 62 · Phase 2 108 · Phase 3 135 · Phase 4 148
First in 1985; this study’s year is marked. 49 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 227 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 70 across the 706 interventional studies, 115 across the 98 observational. Of the 644 that completed or were terminated, 302 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
262 of 807 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
H. Lundbeck A/S has 2 studies filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
34 of the studies in Attention Deficit Disorder with Hyperactivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759154Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | 2027-05-27 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT04946253University of PittsburghSKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care | 2026-11 |
| NCT05683756University of PittsburghOptimizing Attention and Sleep Intervention Study | 2026-12 |
| NCT07594730New York State Psychiatric InstituteBrief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems | 2026-12-01 |
Add all 34 to your calendar (.ics) → With an account.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose is to determine the effect of vortioxetine treatment on ADHD symptoms in adult patients with ADHD in a 12 weeks study.
The study employed the Sequential Parallel Comparison Design (SPCD), a clinical study design which intend to increase signal detection by using two stages of treatment:
In Stage 1, patients were randomized to placebo or vortioxetine 10 or 20mg. Patients on vortioxetine 10 or 20mg/day during Stage 1 remained on the same treatment in Stage 2. Responders to placebo in Stage 1 remained on Placebo in Stage 2. Patients who were placebo non-responders during Stage 1, defined as patients with a \<30% reduction in AISRS total score from Baseline 1, were re-randomized to placebo or vortioxetine 10 or 20mg/day in Stage 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion and exclusion criteria do apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Stage 1, patients will receive vortioxetine 10mg/day for 6 weeks. In Stage 2, patients who received vortioxetine 10mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks.
Drug: vortioxetine 10 mg tablet
In Stage 1, patients will receive vortioxetine 20mg/day for 6 weeks. In Stage 2, patients who received vortioxetine 20mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks.
Drug: vortioxetine 20 mg tablet
In Stage 1, the patients will receive placebo for 6 weeks. In Stage 2, placebo responders will continue on placebo for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks.
Other: Placebo tablet
Oral tablets, once daily
Also known as: Brintellix®, Lu AA21004, Trintellix®
Oral tablets, once daily
Also known as: Brintellix®, Lu AA21004, Trintellix®
Oral tablets, once daily
Change in ADHD Investigator Symptom Rating Scale (AISRS) Total Score
AISRS: an 18-item scale administered by the investigator. It included 9 items that evaluated symptoms of inattention and 9 items that evaluated symptoms of impulsivity and hyperactivity. Each item was rated from 0 (none) to 3 (severe). AISRS total score was calculated as sum of all the items on the scale and ranged from 0 to 54. A higher score corresponded to a worse severity of ADHD.
Time frame: Baseline to Week 6
Inattention/Meta-cognition: Change in Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Using Metacognition Index
The Metacognition Index (MI) is an index score of the BRIEF-A consisting of 5 scales: initiate, working memory, plan/organise, task monitor, and organization of materials. Each item is rated on a 3-point scale with the numeric score of 1 to 3. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Cognitive Function/Global Executive Function: Change in BRIEF-A Using the Global Executive Composite Score
BRIEF-A is a validated questionnaire composed of 75-item within nine non-overlapping scales: 4 scales in the Behavioral Regulation Index (BRI) (inhibit, shift, emotional control, and self-monitor), and 5 scales in the Metacognition Index (MI) (initiate, working memory, plan/organise, task monitor, and organization of materials). Each item is rated on a 3-point scale with the numeric score of 1 to 3. The BRIEF-A yields an overall score (Global Executive Composite) composed of two index scores, the MI and the BRI. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Overall Functioning: Change in Sheehan Disability Scale (SDS) Total Score
The SDS comprises a series of patient rated scales designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and 3) home life or family responsibilities are impaired on a 10-point visual analogue scale, on which 0 = normal functioning and 10 = severe functional impairment. The number of days lost and the number of underproductive days last from work/school due to symptoms are also captured. The total score is calculated as a sum of the 3 visual analogue scales, ranges from 0 to 30. A higher score represents more severe functional impairment. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Productivity: Change in Work Limitations Questionnaire (WLQ) Productivity Loss Score
The WLQ is a patient self-rated scale designed to assess on-the-job impact of chronic health problems and/or treatment. The WLQ consists of 25 items in 4 dimensions: limitations handling time (5 items), physical work demands (6 items), mental-interpersonal work demands (9 items), and output demands (5 items). Each item is rated on a 5-point scale from "All of the Time" (score 5) to "None of the Time" (score 0), or "Does Not Apply to My Job". The WLQ Productivity Loss Score is derived from the Global Productivity Index, which is calculated as a weighed sum of the 4 dimensions. Reduction in WLQ Productivity Loss score indicates less work limitation and represents the estimated percentage of productivity loss in the past two weeks due to presenteeism relative to a healthy benchmark sample. WLQ Productivity Loss Score ranges from 0% to 24,9%.
Time frame: Baseline to Week 6
Change in AISRS Inattention Sub-score
The AISRS inattentive subscale score consists of 9 items from the AISRS which address inattention. Each item is rated from 0 to 3. The AISRS inattentive subscale score can range from 0 to 27. A higher score corresponds to a worse severity of ADHD inattentiveness.
Time frame: Baseline to Week 6
Change AISRS Hyperactivity/Impulsivity Sub-score
The AISRS hyperactive/impulsive subscale score consists of 9 items from the AISRS which address hyperactivity and impulsivity. Each item is rated from 0 to 3. The AISRS hyperactive/impulsive subscale score can range from 0 to 27. A higher score corresponds to a worse severity of ADHD hyperactivity/impulsivity.
Time frame: Baseline to Week 6
Percentage of Patients Responding (Response Defined as 30% or Greater Reduction From Baseline in AISRS Total Score)
AISRS: an 18-item scale administered by the investigator. It included 9 items that evaluated symptoms of inattention and 9 items that evaluated symptoms of impulsivity and hyperactivity. Each item was rated from 0 (none) to 3 (severe). AISRS total score was calculated as sum of all the items on the scale and ranged from 0 to 54. A higher score corresponded to a worse severity of ADHD.
Time frame: Baseline to Week 6
Change in Adult ADHD Self-Report Scale (ASRS) Total Score
The Adult ADHD Self-Report Scale (ASRS) is a patient-rated scale designed to assess the ADHD symptoms in adults based on the diagnostic criteria of DSM-IVTM. The ASRS consist of 18 items, each rated on a 5-point scale from "Never" to "Very Often". The categories "Never" and "Rarely" were combined when calculating the total score to mirror the scoring of the AISRS, with 0 representing "Never"/"Rarely" and 3 representing "Very Often". The Total Score ranges from 0 to 54. A reduction in score indicates less severity of ADHD.
Time frame: Baseline to Week 6
Change in Clinical Global Impression - Severity of Illness (CGI-S) Score
The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). Higher scores indicate worsening.
Time frame: Baseline to Week 6
Clinical Global Impression - Global Improvement (CGI-I) Score
The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Higher scores indicate worsening.
Time frame: Week 6
Response (Defined as a CGI-I Score of 1 or 2), Stage 1
The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Higher scores indicate worsening.
Time frame: Week 6
Change in BRIEF-A Using the Behavioural Regulation Index
The Behavioral Regulation Index (BRI) is an index score of the BRIEF-A and consists of 4 scales: inhibit, shift, emotional control, and self-monitor). Each item is rated on a 3-point scale with the numeric score of 1 to 3. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in BRIEF-A Subscales - Inhibit
The BRIEF-A subscale Inhibit is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change BRIEF-A Subscales - Initiate
The BRIEF-A subscale Initiate is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in BRIEF-A Subscales - Organization of Materials
The BRIEF-A subscale Organization of Materials is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in BRIEF-A Subscales - Planning/Organize
The BRIEF-A subscale Planning/Organize is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in BRIEF-A Subscales - Shift
The BRIEF-A subscale Shift is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in BRIEF-A Subscales - Self Monitor
The BRIEF-A subscale Self Monitor is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in BRIEF-A Subscales - Task Monitor
The BRIEF-A subscale Task Monitor is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in BRIEF-A Subscales - Working Memory
The BRIEF-A subscale Working Memory is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in BRIEF-A Subscales - Emotional Control
The BRIEF-A subscale Emotional Control is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in Perceived Deficits Questionnaire - Depression (PDQ-D) Total Score
The PDQ-D is a patient-rated scale designed to assess cognitive impairment/dysfunction adapted for MDD. Each item is rated on a scale from 0 (never) to 4 (almost always). The total score of the 20 items ranges from 0 to 80 with higher scores reflect greater subjective cognitive impairment. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in PDQ-D Subscales - Attention and Concentration Sub-score
The PDQ-D attention/concentration sub-score consists of items 1, 5, 9, 13, and 17 of the PDQ with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.
Time frame: Baseline to Week 6
Change in PDQ-D Sub-scales - Retrospective Memory Sub-score
The PDQ-D retrospective memory sub-score consists of items 2, 6, 10, 14, and 18 of the PDQ (see Outcome 23) with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.
Time frame: Baseline to Week 6
Change in PDQ-D Sub-scales - Prospective Memory Sub-score
The PDQ-D prospective memory sub-score consists of items 3, 7, 11, 15, and 19 of the PDQ (see Outcome 23) with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.
Time frame: Baseline to Week 6
Change in PDQ-D Sub-scales - Planning and Organisation Sub-score
The PDQ-D planning and organisation sub-score consists of items 4, 8, 12, 16, and 20 of the PDQ (see Outcome 23) with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.
Time frame: Baseline to Week 6
Change in SDS Item Scores - Family
The SDS item family is rated from 0 = normal functioning to 10 = severe functional impairment (see outcome 4). A higher score represents more severe functional impairment. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in SDS Item Scores - Work
The SDS item work is rated from 0 = normal functioning to 10 = severe functional impairment (see outcome 4). A higher score represents more severe functional impairment. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in SDS Item Scores - Social Life
The SDS item social life is rated from 0 = normal functioning to 10 = severe functional impairment (see outcome 4). A higher score represents more severe functional impairment. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in SDS Item Scores - Number of Days Lost
This SDS item captures days lost from school or work (see outcome 4).
Time frame: Baseline to Week 6
Change in SDS Item Scores - Number of Underproductive Days
This SDS item captures the number of underproductive days (see outcome 4)
Time frame: Baseline to Week 6
Change in WLQ Using the Global Productivity Index
The WLQ is a patient self-rated scale designed to assess on-the-job impact of chronic health problems and/or treatment. The WLQ consists of 25 items in 4 dimensions: limitations handling time (5 items), physical work demands (6 items), mental-interpersonal work demands (9 items), and output demands (5 items). Each item is rated on a 5-point scale from "All of the Time" (score 5) to "None of the Time" (score 0), or "Does Not Apply to My Job". The Global Productivity Index is calculated as a weighed sum of the 4 dimensions, and ranges from 0.000 to 0.286. Reduction in score indicates less work limitation.
Time frame: Baseline to Week 6
Change in WLQ Domain Scores - Limitations Handling Time
Limitations Handling Time is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.
Time frame: Baseline to Week 6
Change in WLQ Domain Scores - Mental-Interpersonal Work Demands
Mental-Interpersonal Work Demands is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.
Time frame: Baseline to Week 6
Change in WLQ Domain Scores - Physical Demands
Physical Demands is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.
Time frame: Baseline to Week 6
Change in WLQ Domain Scores - Output Demands
Output Demands is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.
Time frame: Baseline to Week 6
Change in Adult ADHD Quality of Life Measure (AAQoL) Total Score
The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Total score is based on all 29 items and ranges from 29 to 145. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in AAQoL Subscales - Life Productivity Sub-score
The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Life productivity subscale is based on 11 items and ranges from 11 to 55. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in AAQoL Subscales - Psychological Health Sub-score
The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Psychological Health subscale is based on 6 items and ranges from 6 to 30. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in AAQoL Subscales - Life Outlook Sub-score
The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Life Outlook subscale is based on 7 items and ranges from 7 to 35. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
Change in AAQoL Subscales - Relationships Sub-score
The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Relationship subscale is based on 5 items and ranges from 5 to 25. A reduction in score indicates less impairment.
Time frame: Baseline to Week 6
| Milestone | Vortioxetine 10mg | Vortioxetine 20mg | Placebo - Placebo | Placebo - Vortioxetine 10mg | Placebo - Vortioxetine 20mg |
|---|---|---|---|---|---|
| Started | 49 | 45 | 96 | 21 | 16 |
| Completed | 36 | 29 | 54 | 20 | 12 |
| Not completed | 13 | 16 | 42 | 1 | 4 |
| Withdrew: Adverse event | 4 | 4 | 3 | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 0 | 5 | 0 | 1 |
| Withdrew: Non-compliance with imp | 1 | 2 | 7 | 0 | 0 |
| Withdrew: Withdrawal of consent | 1 | 0 | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 4 | 5 | 0 | 0 |
| Withdrew: Administrative or other reason(s) | 1 | 5 | 11 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 3 | 0 | 1 |
| Withdrew: Withdrawal before treatment | 2 | 1 | 5 | 0 | 0 |
AISRS: an 18-item scale administered by the investigator. It included 9 items that evaluated symptoms of inattention and 9 items that evaluated symptoms of impulsivity and hyperactivity. Each item was rated from 0 (none) to 3 (severe). AISRS total score was calculated as sum of all the items on the scale and ranged from 0 to 54. A higher score corresponded to a worse severity of ADHD.
| units on a scale | Placebo, Stage 1 | Vortioxetine 10mg, Stage 1 | Vortioxetine 20mg, Stage 1 | Placebo, Stage 2 | Vortioxetine 10mg, Stage 2 | Vortioxetine 20mg, Stage 2 | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|---|---|---|---|---|---|
| Change in ADHD Investigator Symptom Rating Scale (AISRS) Total Score | -12.4 ± 1.25 | -12.8 ± 1.99 | -11.6 ± 2.17 | -4.1 ± 1.92 | -3.9 ± 1.98 | -2.9 ± 2.35 | -8.3 ± 1.1 | -8.3 ± 1.4 | -7.3 ± 1.6 |
The Metacognition Index (MI) is an index score of the BRIEF-A consisting of 5 scales: initiate, working memory, plan/organise, task monitor, and organization of materials. Each item is rated on a 3-point scale with the numeric score of 1 to 3. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-score | Placebo, Stage 1 | Vortioxetine 10mg, Stage 1 | Vortioxetine 20mg, Stage 1 | Placebo, Stage 2 | Vortioxetine 10mg, Stage 2 | Vortioxetine 20mg, Stage 2 | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|---|---|---|---|---|---|
| Inattention/Meta-cognition: Change in Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Using Metacognition Index | -10.0 ± 1.26 | -11.2 ± 1.98 | -10.2 ± 2.16 | -3.1 ± 2.28 | -2.6 ± 2.34 | 0.9 ± 2.84 | -6.5 ± 1.3 | -6.9 ± 1.5 | -4.6 ± 1.8 |
BRIEF-A is a validated questionnaire composed of 75-item within nine non-overlapping scales: 4 scales in the Behavioral Regulation Index (BRI) (inhibit, shift, emotional control, and self-monitor), and 5 scales in the Metacognition Index (MI) (initiate, working memory, plan/organise, task monitor, and organization of materials). Each item is rated on a 3-point scale with the numeric score of 1 to 3. The BRIEF-A yields an overall score (Global Executive Composite) composed of two index scores, the MI and the BRI. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-score | Placebo, Stage 1 | Vortioxetine 10mg, Stage 1 | Vortioxetine 20mg, Stage 1 | Placebo, Stage 2 | Vortioxetine 10mg, Stage 2 | Vortioxetine 20mg, Stage 2 | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|---|---|---|---|---|---|
| Cognitive Function/Global Executive Function: Change in BRIEF-A Using the Global Executive Composite Score | -9.9 ± 1.22 | -12.5 ± 1.93 | -11.4 ± 2.10 | -3.0 ± 2.24 | -3.5 ± 2.31 | 2.1 ± 2.80 | -6.5 ± 1.3 | -8.0 ± 1.5 | -4.6 ± 1.8 |
The SDS comprises a series of patient rated scales designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and 3) home life or family responsibilities are impaired on a 10-point visual analogue scale, on which 0 = normal functioning and 10 = severe functional impairment. The number of days lost and the number of underproductive days last from work/school due to symptoms are also captured. The total score is calculated as a sum of the 3 visual analogue scales, ranges from 0 to 30. A higher score represents more severe functional impairment. A reduction in score indicates less impairment.
| units on a scale | Placebo, Stage 1 | Vortioxetine 10mg, Stage 1 | Vortioxetine 20mg, Stage 1 | Placebo, Stage 2 | Vortioxetine 10mg, Stage 2 | Vortioxetine 20mg, Stage 2 | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|---|---|---|---|---|---|
| Overall Functioning: Change in Sheehan Disability Scale (SDS) Total Score | -5.3 ± 0.74 | -7.9 ± 1.20 | -7.4 ± 1.29 | 0.6 ± 0.91 | -0.9 ± 0.95 | -1.4 ± 1.14 | -2.4 ± 0.6 | -4.4 ± 0.8 | -4.4 ± 0.9 |
The WLQ is a patient self-rated scale designed to assess on-the-job impact of chronic health problems and/or treatment. The WLQ consists of 25 items in 4 dimensions: limitations handling time (5 items), physical work demands (6 items), mental-interpersonal work demands (9 items), and output demands (5 items). Each item is rated on a 5-point scale from "All of the Time" (score 5) to "None of the Time" (score 0), or "Does Not Apply to My Job". The WLQ Productivity Loss Score is derived from the Global Productivity Index, which is calculated as a weighed sum of the 4 dimensions. Reduction in WLQ Productivity Loss score indicates less work limitation and represents the estimated percentage of productivity loss in the past two weeks due to presenteeism relative to a healthy benchmark sample. WLQ Productivity Loss Score ranges from 0% to 24,9%.
| percentage of days lost | Placebo, Stage 1 | Vortioxetine 10mg, Stage 1 | Vortioxetine 20mg, Stage 1 | Placebo, Stage 2 | Vortioxetine 10mg, Stage 2 | Vortioxetine 20mg, Stage 2 | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|---|---|---|---|---|---|
| Productivity: Change in Work Limitations Questionnaire (WLQ) Productivity Loss Score | -2.4 ± 0.54 | -2.5 ± 0.84 | -2.4 ± 0.96 | -0.8 ± 1.02 | -0.9 ± 0.97 | -0.7 ± 1.20 | -1.6 ± 0.6 | -1.7 ± 0.6 | -1.5 ± 0.8 |
The AISRS inattentive subscale score consists of 9 items from the AISRS which address inattention. Each item is rated from 0 to 3. The AISRS inattentive subscale score can range from 0 to 27. A higher score corresponds to a worse severity of ADHD inattentiveness.
| units on a scale | Placebo, Stage 1 | Vortioxetine 10mg, Stage 1 | Vortioxetine 20mg, Stage 1 | Placebo, Stage 2 | Vortioxetine 10mg, Stage 2 | Vortioxetine 20mg, Stage 2 | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|---|---|---|---|---|---|
| Change in AISRS Inattention Sub-score | -6.5 ± 0.71 | -6.0 ± 1.14 | -5.9 ± 1.24 | -1.9 ± 1.2 | -2.0 ± 1.21 | -1.6 ± 1.48 | -4.2 ± 0.7 | -4.0 ± 0.8 | -3.8 ± 1.0 |
The AISRS hyperactive/impulsive subscale score consists of 9 items from the AISRS which address hyperactivity and impulsivity. Each item is rated from 0 to 3. The AISRS hyperactive/impulsive subscale score can range from 0 to 27. A higher score corresponds to a worse severity of ADHD hyperactivity/impulsivity.
| units on a scale | Placebo, Stage 1 | Vortioxetine 10mg, Stage 1 | Vortioxetine 20mg, Stage 1 | Placebo, Stage 2 | Vortioxetine 10mg, Stage 2 | Vortioxetine 20mg, Stage 2 | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|---|---|---|---|---|---|
| Change AISRS Hyperactivity/Impulsivity Sub-score | -5.9 ± 0.62 | -7.0 ± 0.99 | -5.7 ± 1.08 | -2.1 ± 0.93 | -2.0 ± 0.97 | -1.2 ± 1.15 | -4.0 ± 0.6 | -4.5 ± 0.7 | -3.4 ± 0.8 |
AISRS: an 18-item scale administered by the investigator. It included 9 items that evaluated symptoms of inattention and 9 items that evaluated symptoms of impulsivity and hyperactivity. Each item was rated from 0 (none) to 3 (severe). AISRS total score was calculated as sum of all the items on the scale and ranged from 0 to 54. A higher score corresponded to a worse severity of ADHD.
| percentage of participants | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Percentage of Patients Responding (Response Defined as 30% or Greater Reduction From Baseline in AISRS Total Score) | 30.9 | 27.5 | 23.1 |
The Adult ADHD Self-Report Scale (ASRS) is a patient-rated scale designed to assess the ADHD symptoms in adults based on the diagnostic criteria of DSM-IVTM. The ASRS consist of 18 items, each rated on a 5-point scale from "Never" to "Very Often". The categories "Never" and "Rarely" were combined when calculating the total score to mirror the scoring of the AISRS, with 0 representing "Never"/"Rarely" and 3 representing "Very Often". The Total Score ranges from 0 to 54. A reduction in score indicates less severity of ADHD.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in Adult ADHD Self-Report Scale (ASRS) Total Score | -4.9 ± 1.0 | -6.5 ± 1.3 | -3.4 ± 1.4 |
The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). Higher scores indicate worsening.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in Clinical Global Impression - Severity of Illness (CGI-S) Score | -0.5 ± 0.1 | -0.7 ± 0.1 | -0.6 ± 0.1 |
The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Higher scores indicate worsening.
| units on a scale | Placebo, Stage 1 | Vortioxetine 10mg, Stage 1 | Vortioxetine 20mg, Stage 1 |
|---|---|---|---|
| Clinical Global Impression - Global Improvement (CGI-I) Score | 3.01 ± 0.11 | 2.93 ± 0.17 | 3.15 ± 0.18 |
The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Higher scores indicate worsening.
| percentages of participants | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Response (Defined as a CGI-I Score of 1 or 2), Stage 1 | 43 | 13 | 11 |
The Behavioral Regulation Index (BRI) is an index score of the BRIEF-A and consists of 4 scales: inhibit, shift, emotional control, and self-monitor). Each item is rated on a 3-point scale with the numeric score of 1 to 3. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-score | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in BRIEF-A Using the Behavioural Regulation Index | -5.3 ± 1.1 | -7.9 ± 1.3 | -3.9 ± 1.6 |
The BRIEF-A subscale Inhibit is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-score | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in BRIEF-A Subscales - Inhibit | -5.5 ± 1.4 | -8.6 ± 1.5 | -3.2 ± 1.8 |
The BRIEF-A subscale Initiate is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-score | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change BRIEF-A Subscales - Initiate | -6.2 ± 1.4 | -5.8 ± 1.6 | -4.2 ± 1.8 |
The BRIEF-A subscale Organization of Materials is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-score | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in BRIEF-A Subscales - Organization of Materials | -4.4 ± 1.1 | -6.3 ± 1.3 | -3.2 ± 1.5 |
The BRIEF-A subscale Planning/Organize is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-score | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in BRIEF-A Subscales - Planning/Organize | -8.2 ± 1.6 | -8.7 ± 1.8 | -6.8 ± 2.1 |
The BRIEF-A subscale Shift is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-score | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in BRIEF-A Subscales - Shift | -5.6 ± 1.4 | -9.1 ± 1.6 | -3.5 ± 1.9 |
The BRIEF-A subscale Self Monitor is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-score | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in BRIEF-A Subscales - Self Monitor | -6.5 ± 1.4 | -11.0 ± 1.6 | -4.8 ± 1.8 |
The BRIEF-A subscale Task Monitor is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-score | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in BRIEF-A Subscales - Task Monitor | -6.4 ± 1.5 | -7.8 ± 1.7 | -4.9 ± 2.0 |
The BRIEF-A subscale Working Memory is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-score | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in BRIEF-A Subscales - Working Memory | -7.6 ± 1.6 | -9.9 ± 1.8 | -3.8 ± 2.1 |
The BRIEF-A subscale Emotional Control is a subscale within the Behavioural Regulation Index (BRI). Each item is rated on a 3-point scale ranging from 1 (never) to 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-score | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in BRIEF-A Subscales - Emotional Control | -3.4 ± 1.0 | -4.8 ± 1.1 | -3.5 ± 1.4 |
The PDQ-D is a patient-rated scale designed to assess cognitive impairment/dysfunction adapted for MDD. Each item is rated on a scale from 0 (never) to 4 (almost always). The total score of the 20 items ranges from 0 to 80 with higher scores reflect greater subjective cognitive impairment. A reduction in score indicates less impairment.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in Perceived Deficits Questionnaire - Depression (PDQ-D) Total Score | -7.6 ± 1.6 | -9.3 ± 2.0 | -6.3 ± 2.2 |
The PDQ-D attention/concentration sub-score consists of items 1, 5, 9, 13, and 17 of the PDQ with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in PDQ-D Subscales - Attention and Concentration Sub-score | -1.7 ± 0.4 | -2.3 ± 0.5 | -1.8 ± 0.6 |
The PDQ-D retrospective memory sub-score consists of items 2, 6, 10, 14, and 18 of the PDQ (see Outcome 23) with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in PDQ-D Sub-scales - Retrospective Memory Sub-score | -1.8 ± 0.5 | -2.4 ± 0.6 | -1.5 ± 0.6 |
The PDQ-D prospective memory sub-score consists of items 3, 7, 11, 15, and 19 of the PDQ (see Outcome 23) with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in PDQ-D Sub-scales - Prospective Memory Sub-score | -1.5 ± 0.4 | -2.3 ± 0.5 | -0.9 ± 0.6 |
The PDQ-D planning and organisation sub-score consists of items 4, 8, 12, 16, and 20 of the PDQ (see Outcome 23) with a score ranging from 0 to 20. A higher score reflects greater subjective cognitive impairment. A reduction in score indicates less cognitive impairment.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in PDQ-D Sub-scales - Planning and Organisation Sub-score | -2.4 ± 0.5 | -2.5 ± 0.6 | -1.9 ± 0.7 |
The SDS item family is rated from 0 = normal functioning to 10 = severe functional impairment (see outcome 4). A higher score represents more severe functional impairment. A reduction in score indicates less impairment.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in SDS Item Scores - Family | -1.5 ± 0.3 | -1.8 ± 0.3 | -1.5 ± 0.4 |
The SDS item work is rated from 0 = normal functioning to 10 = severe functional impairment (see outcome 4). A higher score represents more severe functional impairment. A reduction in score indicates less impairment.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in SDS Item Scores - Work | -1.2 ± 0.3 | -2.0 ± 0.4 | -2.1 ± 0.4 |
The SDS item social life is rated from 0 = normal functioning to 10 = severe functional impairment (see outcome 4). A higher score represents more severe functional impairment. A reduction in score indicates less impairment.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in SDS Item Scores - Social Life | -1.1 ± 0.3 | -1.7 ± 0.3 | -1.5 ± 0.4 |
This SDS item captures days lost from school or work (see outcome 4).
| days | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in SDS Item Scores - Number of Days Lost | -0.3 ± 0.1 | -0.2 ± 0.1 | -0.1 ± 0.2 |
This SDS item captures the number of underproductive days (see outcome 4)
| days | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in SDS Item Scores - Number of Underproductive Days | -1.2 ± 0.3 | -1.0 ± 0.3 | -1.2 ± 0.3 |
The WLQ is a patient self-rated scale designed to assess on-the-job impact of chronic health problems and/or treatment. The WLQ consists of 25 items in 4 dimensions: limitations handling time (5 items), physical work demands (6 items), mental-interpersonal work demands (9 items), and output demands (5 items). Each item is rated on a 5-point scale from "All of the Time" (score 5) to "None of the Time" (score 0), or "Does Not Apply to My Job". The Global Productivity Index is calculated as a weighed sum of the 4 dimensions, and ranges from 0.000 to 0.286. Reduction in score indicates less work limitation.
| Index | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in WLQ Using the Global Productivity Index | -0.0 ± 0.0 | -0.0 ± 0.0 | -0.0 ± 0.0 |
Limitations Handling Time is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in WLQ Domain Scores - Limitations Handling Time | -5.6 ± 2.7 | -7.7 ± 3.1 | -2.2 ± 3.7 |
Mental-Interpersonal Work Demands is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in WLQ Domain Scores - Mental-Interpersonal Work Demands | -8.4 ± 2.2 | -8.2 ± 2.6 | -6.2 ± 2.9 |
Physical Demands is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in WLQ Domain Scores - Physical Demands | -5.5 ± 2.4 | -5.0 ± 2.9 | -4.6 ± 3.2 |
Output Demands is scored on a scale of 0 (limited at work none of the time) to 100 (limited at work all of the time) based on a converted mean score. A reduction in score indicates less work limitation.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in WLQ Domain Scores - Output Demands | -8.9 ± 3.1 | -7.1 ± 3.5 | -7.2 ± 4.0 |
The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Total score is based on all 29 items and ranges from 29 to 145. A reduction in score indicates less impairment.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in Adult ADHD Quality of Life Measure (AAQoL) Total Score | 7.7 ± 1.7 | 9.1 ± 2.1 | 5.4 ± 2.3 |
The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Life productivity subscale is based on 11 items and ranges from 11 to 55. A reduction in score indicates less impairment.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in AAQoL Subscales - Life Productivity Sub-score | 10.9 ± 2.4 | 11.6 ± 2.8 | 6.4 ± 3.1 |
The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Psychological Health subscale is based on 6 items and ranges from 6 to 30. A reduction in score indicates less impairment.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in AAQoL Subscales - Psychological Health Sub-score | 6.7 ± 2.2 | 10.3 ± 2.5 | 5.7 ± 2.7 |
The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Life Outlook subscale is based on 7 items and ranges from 7 to 35. A reduction in score indicates less impairment.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in AAQoL Subscales - Life Outlook Sub-score | 3.7 ± 1.3 | 5.0 ± 1.7 | 3.0 ± 1.8 |
The AAQoL is a patient-rated scale designed to assess health-related quality of life in adults with ADHD. The AAQoL consists of 29 items, each item is rated on a 5-point scale from 1 (not at all/never) to 5 (extremely/very often). The AAQoL Relationship subscale is based on 5 items and ranges from 5 to 25. A reduction in score indicates less impairment.
| units on a scale | Placebo, Combined | Vortioxetine 10mg, Combined | Vortioxetine 20mg, Combined |
|---|---|---|---|
| Change in AAQoL Subscales - Relationships Sub-score | 7.4 ± 2.1 | 8.1 ± 2.5 | 6.0 ± 2.7 |
Collected over Baseline to end of study (16 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-Placebo | 0/91 (0%) | 1/91 (1.1%) | 39/91 (42.9%) |
| Vortioxetine 10mg | 0/68 (0%) | 1/68 (1.5%) | 34/68 (50%) |
| Vortioxetine 20mg | 0/60 (0%) | 0/60 (0%) | 36/60 (60%) |
| Event | Placebo-Placebo | Vortioxetine 10mg | Vortioxetine 20mg |
|---|---|---|---|
| Suicidal ideationPsychiatric disorders | 0/91 | 1/68 | 0/60 |
| ConcussionInjury, poisoning and procedural complications | 1/91 | 0/68 | 0/60 |
| Event | Placebo-Placebo | Vortioxetine 10mg | Vortioxetine 20mg |
|---|---|---|---|
| NauseaGastrointestinal disorders | 3/91 | 15/68 | 18/60 |
| HeadacheNervous system disorders | 17/91 | 10/68 | 10/60 |
| FatigueGeneral disorders | 10/91 | 7/68 | 11/60 |
| InsomniaPsychiatric disorders | 9/91 | 4/68 | 5/60 |
| DiarrhoeaGastrointestinal disorders | 3/91 | 4/68 | 5/60 |
| Weight increasedInvestigations | 2/91 | 5/68 | 3/60 |
| NasopharyngitisInfections and infestations | 4/91 | 2/68 | 4/60 |
| Abdominal pain upperGastrointestinal disorders | 2/91 | 4/68 | 0/60 |
| VomitingGastrointestinal disorders | 1/91 | 4/68 | 3/60 |
| DizzinessNervous system disorders | 4/91 | 4/68 | 2/60 |
| Age, Continuous(years) | Placebo (Stage 1) | Vortioxetine 10mg (Stage 1) | Vortioxetine 20mg (Stage 1) | Total |
|---|---|---|---|---|
| Mean | 37.1 ± 10.3 | 35.8 ± 9.6 | 37.2 ± 10.4 | 36.9 ± 10.2 |
| Sex: Female, Male(Participants) | Placebo (Stage 1) | Vortioxetine 10mg (Stage 1) | Vortioxetine 20mg (Stage 1) | Total |
|---|---|---|---|---|
| Female | 66 | 24 | 19 | 109 |
| Male | 62 | 23 | 25 | 110 |
| Race (NIH/OMB)(Participants) | Placebo (Stage 1) | Vortioxetine 10mg (Stage 1) | Vortioxetine 20mg (Stage 1) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 8 | 4 | 1 | 13 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 0 | 3 |
| Black or African American | 15 | 3 | 8 | 26 |
| White | 97 | 37 | 31 | 165 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 2 | 4 | 12 |
The record gives a start of Dec 2014, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2018, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine
Attention Deficit Disorder with Hyperactivity →